주사 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Rosacea Market Outlook

Thelansis's "Rosacea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rosacea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Rosacea Overview

Rosacea is a chronic, multifaceted inflammatory skin condition that can present as persistent facial redness, visible blood vessels, inflammatory bumps, or thickened skin, often in overlapping combinations that have historically required patients to combine several topical treatments, each addressing only one symptom at a time. Oral antibiotics targeting inflammatory lesions have long anchored systemic care, but for years no approved therapy addressed both the inflammatory and vascular, redness-driving components together, forcing a fragmented approach even for well-managed patients. That gap narrowed recently with a new extended-release oral therapy shown to improve both dimensions simultaneously, positioning it as a potential new standard rather than another incremental topical option. Deeper research into the disease's underlying biology, including immune activation, skin barrier dysfunction, and the skin microbiome, continues to inform where the next targeted therapies may emerge. For stakeholders, rosacea shows a common, chronic condition still consolidating around more comprehensive systemic solutions rather than an ever-growing list of symptom-specific products.

Key Highlights

• In Germany, diagnosed Rosacea cases are projected to increase from 2,501,746 in 2025 to 2,819,254 by 2035.
• Rosacea is a chronic inflammatory skin disorder characterized by persistent facial erythema, flushing, and inflammatory lesions.
• The disease significantly impacts patients' quality of life, with frequent relapses requiring long-term management.
• Significant unmet need remains for therapies that provide sustained symptom control and reduce disease recurrence.

Market Overview

• The France Rosacea market is projected to grow from $48M in 2025 to $98M by 2035.
• Market growth is driven by:
• Increasing diagnosis and disease awareness
• Growing adoption of targeted topical and systemic therapies
• Future growth will depend on therapies offering durable disease control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CAGE Bio Inc.
• Tarsus Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)